Quest Diagnostics Q3 revenue rises 10%, raises full-year revenue and EPS guidance

Quest Diagnostics reported a 10% revenue increase to $3.10 billion in Q3 2026, driven by strong organic growth across physician, hospital, and consumer channels. Adjusted EPS rose 15.4% to $3.00, reflecting productivity gains from automation and AI. The company raised its full-year 2026 revenue forecast to $12.065-$12.105 billion and adjusted EPS guidance to $11.25-$11.35, citing robust demand and new product launches including expanded Alzheimer's testing. Quest continues strategic acquisitions and technology investments, aiming to deploy new lab solutions by late 2027.

Quest Diagnostics shares are trading at USD 228.00 on Pluang, down 4.47% for the day as of Oct 22, 2026 18:02 WIB. The stock's market cap stands at $26.37 billion, with a dividend yield of 1.44%.